Take a deeper dive

Webinar | Cellular & Gene Therapy 101

This webinar covers an introduction to cellular and gene therapies, which both use the body’s own cells and genetic information to fight diseases but do so in different ways. Cellular therapy uses actual cells as the therapy, whereas gene therapy alters the genetic material of a patient. Both types of therapies offer huge promise to treating and curing diseases that until recently had no treatment options.

While any drug development program can face pitfalls and uncertainties, developing cellular and gene therapies often present unique challenges above and beyond those encountered for small molecule drugs.

At the end of this webinar, attendees should have a better understanding of:

  • Basic understanding of cellular and gene therapy
  • Issues in integrating and non-integrating vectors
  • Challenges in selecting First-in-Human (FIH) doses for cellular and gene therapy

Meet the Presenter

Devin Welty, Ph.D.
Senior Consultant, Nonclinical & Clinical Pharmacology

Dr. Welty has over 25 years of experience in preclinical and clinical pharmacology leading organizations and project teams from early discovery to approval and commercialization, most recently as the Global Head of DMPK at Shire. He has extensive experience in pharmacokinetics, pharmacodynamics, systems pharmacology, and model-informed approaches for candidate nomination and efficient clinical development strategy. He has supported the successful submission of more than 50 INDs/CTAs and more than 20 NDAs/MAAs/BLAs for small molecules, biologics, and gene therapy therapeutics.

Explore Our Blog

FDA Orphan Drug Designation for Rare Diseases

An estimated 30 million people in the United States are afflicted with rare (orphan) diseases or conditions; however, the availability…

Read More
T cells around a cancer cell

CAR T-Cell Therapy Challenges to Development & Approval

Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary immunotherapy that uses cells from the patient’s immune system to…

Read More

What is a 505(b)(2)?

The 505(b)(2) New Drug Application (NDA) is a streamlined NDA process in which the applicant relies upon one or more…

Read More